These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21603983)

  • 1. Cancer worry among Norwegian male BRCA1/2 mutation carriers.
    Strømsvik N; Råheim M; Gjengedal E
    Fam Cancer; 2011 Sep; 10(3):597-603. PubMed ID: 21603983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.
    Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
    Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An exploration of the communication preferences regarding genetic testing in individuals from families with identified breast/ovarian cancer mutations.
    Ratnayake P; Wakefield CE; Meiser B; Suthers G; Price MA; Duffy J; ; Tucker K
    Fam Cancer; 2011 Mar; 10(1):97-105. PubMed ID: 20878485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.
    Høberg-Vetti H; Bjorvatn C; Fiane BE; Aas T; Woie K; Espelid H; Rusken T; Eikesdal HP; Listøl W; Haavind MT; Knappskog PM; Haukanes BI; Steen VM; Hoogerbrugge N
    Eur J Hum Genet; 2016 Jun; 24(6):881-8. PubMed ID: 26350514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
    Kwong A; Chu AT
    Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
    Bakos AD; Hutson SP; Loud JT; Peters JA; Giusti RM; Greene MH
    Health Expect; 2008 Sep; 11(3):220-31. PubMed ID: 18816319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling.
    Liede A; Metcalfe K; Hanna D; Hoodfar E; Snyder C; Durham C; Lynch HT; Narod SA
    Am J Hum Genet; 2000 Dec; 67(6):1494-504. PubMed ID: 11063672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences.
    Hurley K; Rubin LR; Werner-Lin A; Sagi M; Kemel Y; Stern R; Phillips A; Cholst I; Kauff N; Offit K
    Cancer; 2012 Dec; 118(24):6270-7. PubMed ID: 22736296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2.
    Adams I; Christopher J; Williams KP; Sheppard VB
    J Cancer Educ; 2015 Jun; 30(2):344-52. PubMed ID: 25301325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2005 Mar; 133A(2):165-9. PubMed ID: 15633195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproductive decision-making in young female carriers of a BRCA mutation.
    Donnelly LS; Watson M; Moynihan C; Bancroft E; Evans DG; Eeles R; Lavery S; Ormondroyd E
    Hum Reprod; 2013 Apr; 28(4):1006-12. PubMed ID: 23293217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
    DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
    Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial communication and cascade testing among relatives of BRCA population screening participants.
    Lieberman S; Lahad A; Tomer A; Koka S; BenUziyahu M; Raz A; Levy-Lahad E
    Genet Med; 2018 Nov; 20(11):1446-1454. PubMed ID: 29595811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Living with the BRCA genetic mutation: an uncertain conclusion to an unending process.
    DiMillo J; Samson A; Thériault A; Lowry S; Corsini L; Verma S; Tomiak E
    Psychol Health Med; 2013; 18(2):125-34. PubMed ID: 22670560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London.
    Kohut K; D'Mello L; Bancroft EK; Thomas S; Young MA; Myhill K; Shanley S; Briggs BH; Newman M; Saraf IM; Cox P; Scambler S; Wagman L; Wyndham MT; Eeles RA; Ferris M
    Fam Cancer; 2012 Mar; 11(1):107-13. PubMed ID: 22016143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finding all BRCA pathogenic mutation carriers: best practice models.
    Hoogerbrugge N; Jongmans MC
    Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S19-26. PubMed ID: 27514840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychological distress related to BRCA testing in ovarian cancer patients.
    Bjørnslett M; Dahl AA; Sørebø Ø; Dørum A
    Fam Cancer; 2015 Dec; 14(4):495-504. PubMed ID: 25980896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
    Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
    J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.